Efficacy and Safety of Anlotinib for Patients with Advanced NSCLC Who Progressed After Standard Regimens and the Preliminary Analysis of an Efficacy Predictor
Authors Cheng JD, Chai LX, Zhao ZP, Hao YY, Li S
Received 10 March 2020
Accepted for publication 12 June 2020
Published 12 July 2020 Volume 2020:12 Pages 5641—5650
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 2
Editor who approved publication: Dr Eileen O'Reilly
Jian-De Cheng,1,* Li-Xun Chai,2,* Zhi-Ping Zhao,1 Yan-Yan Hao,1 Shuo Li3
1Department of Respiratory and Critical Care Medicine, The Shanxi Bethune Hospital, Taiyuan 030032, Shanxi, People’s Republic of China; 2Department of Thoracic Surgery, The Shanxi Bethune Hospital, Taiyuan 030032, Shanxi, People’s Republic of China; 3Department of Respiratory and Critical Medicine, Tianjin Medical University General Hospital, Tianjin 300052, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Shuo Li
Department of Respiratory and Critical Medicine, Tianjin Medical University General Hospital, Tianjin 300052, People’s Republic of China
Tel +86 13512279233
Background: The aim of this study was to investigate the efficacy and safety of anlotinib for patients with advanced non-small cell lung cancer (NSCLC) who progressed after standard regimens in real world situations and the preliminary analysis of an efficacy predictor.
Methods: A total of 118 patients with advanced NSCLC who progressed after standard regimens were included in this retrospective study. Efficacy was evaluated and toxicity profile was recorded. Progression-free survival (PFS) and overall survival (OS) were assessed using Kaplan–Meier survival curve and multivariate analysis was adjusted using Cox regression analysis.
Results: All of the 118 patients with NSCLC were available for evaluation of efficacy. Complete response (CR, 0 case), partial response (PR, 10 cases), stable disease (SD, 79 cases) and progressive disease (PD, 29 cases) were evaluated according to RECIST version 1.1. In consequence, objective response rate (ORR) was 8.47% and disease control rate (DCR) was 75.42%. The median PFS of the 118 patients with NSCLC was 4.3 months and the median OS was 10.3 months. The results of Cox regression analysis suggested that ECOG score was an independent factor for PFS. The toxicity profile indicated that hypertension and hand-foot syndrome were the most common adverse reactions. Additionally, the preliminary analysis of an efficacy predictor suggested that the PFS of patients with hypertension was superior to those without hypertension.
Conclusion: Anlotinib is effective and safe for patients with advanced NSCLC who progressed after standard regimens in real world situations. Hypertension may be a biomarker for efficacy prediction.
Keywords: non-small cell lung cancer, anlotinib, efficacy, safety, biomarker
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]